Tumor Dosimetry Using [124I]m-iodobenzylguanidine MicroPET/CT for [131I]m-iodobenzylguanidine Treatment of Neuroblastoma in a Murine Xenograft Model

Overview

Journal Mol Imaging Biol

Publisher Springer

Specialties Molecular Biology
Radiology

Date 2012 Mar 3

PMID 22382618

Citations 22

Authors

Youngho Seo

W Clay Gustafson

Shorouk F Dannoon

Erin A Nekritz

Chang-Lae Lee

Stephanie T Murphy

Henry F VanBrocklin

Miguel Hernandez-Pampaloni

Daphne A Haas-Kogan

William A Weiss

Katherine K Matthay

Affiliations

Soon will be listed here.

Abstract

Purpose: [(124)I]m-iodobenzylguanidine ((124)I-mIBG) provides a quantitative tool for pretherapy tumor imaging and dosimetry when performed before [(131)I]m-iodobenzylguanidine ((131)I-mIBG) targeted radionuclide therapy of neuroblastoma. (124)I (T (1/2) = 4.2 days) has a comparable half-life to that of (131)I (T (1/2) = 8.02 days) and can be imaged by positron emission tomography (PET) for accurate quantification of the radiotracer distribution. We estimated expected radiation dose in tumors from (131)I-mIBG therapy using (124)I-mIBG microPET/CT imaging data in a murine xenograft model of neuroblastoma transduced to express high levels of the human norepinephrine transporter (hNET).

Procedures: In order to enhance mIBG uptake for in vivo imaging and therapy, NB 1691-luciferase (NB1691) human neuroblastoma cells were engineered to express high levels of hNET protein by lentiviral transduction (NB1691-hNET). Both NB1691 and NB1691-hNET cells were implanted subcutaneously and into renal capsules in athymic mice. (124)I-mIBG (4.2-6.5 MBq) was administered intravenously for microPET/CT imaging at 5 time points over 95 h (0.5, 3-5, 24, 48, and 93-95 h median time points). In vivo biodistribution data in normal organs, tumors, and whole-body were collected from reconstructed PET images corrected for photon attenuation using the CT-based attenuation map. Organ and tumor dosimetry were determined for (124)I-mIBG. Dose estimates for (131)I-mIBG were made, assuming the same in vivo biodistribution as (124)I-mIBG.

Results: All NB1691-hNET tumors had significant uptake and retention of (124)I-mIBG, whereas unmodified NB1691 tumors did not demonstrate quantifiable mIBG uptake in vivo, despite in vitro uptake. (124)I-mIBG with microPET/CT provided an accurate three-dimensional tool for estimating the radiation dose that would be delivered with (131)I-mIBG therapy. For example, in our model system, we estimated that the administration of (131)I-mIBG in the range of 52.8-206 MBq would deliver 20 Gy to tumors.

Conclusions: The overexpression of hNET was found to be critical for (124)I-mIBG uptake and retention in vivo. The quantitative (124)I-mIBG PET/CT is a promising new tool to predict tumor radiation doses with (131)I-mIBG therapy of neuroblastoma. This methodology may be applied to tumor dosimetry of (131)I-mIBG therapy in human subjects using (124)I-mIBG pretherapy PET/CT data.

Citing Articles

Aurora Kinase A inhibition enhances DNA damage and tumor cell death with I-MIBG therapy in high-risk neuroblastoma.

Kumar P, Koach J, Nekritz E, Mukherjee S, Braun B, Dubois S EJNMMI Res. 2024; 14(1):54.

PMID: 38869684 PMC: 11176152. DOI: 10.1186/s13550-024-01112-7.

Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma.

Batra V, Samanta M, Makvandi M, Groff D, Martorano P, Elias J Clin Cancer Res. 2022; 28(18):4146-4157.

PMID: 35861867 PMC: 9475242. DOI: 10.1158/1078-0432.CCR-22-0400.

Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade.

Crisan G, Moldovean-Cioroianu N, Timaru D, Andries G, Cainap C, Chis V Int J Mol Sci. 2022; 23(9).

PMID: 35563414 PMC: 9103893. DOI: 10.3390/ijms23095023.

Diagnostic Performance of I-Metaiodobenzylguanidine PET/CT in Patients with Pheochromocytoma.

Weber M, Schmitz J, Maric I, Pabst K, Umutlu L, Walz M J Nucl Med. 2021; 63(6):869-874.

PMID: 34556526 PMC: 9157725. DOI: 10.2967/jnumed.121.262797.

Nuclear Medicine Imaging in Neuroblastoma: Current Status and New Developments.

Samim A, Tytgat G, Bleeker G, Wenker S, Chatalic K, Poot A J Pers Med. 2021; 11(4).

PMID: 33916640 PMC: 8066332. DOI: 10.3390/jpm11040270.

References

More S, Itsara M, Yang X, Geier E, Tadano M, Seo Y . Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems. Clin Cancer Res. 2011; 17(8):2339-49. PMC: 3247296. DOI: 10.1158/1078-0432.CCR-10-2949. View

Short J, DARBY T . Sympathetic nervous system blocking agents. 3. Derivatives of benzylguanidine. J Med Chem. 1967; 10(5):833-40. DOI: 10.1021/jm00317a017. View

Moroz M, Serganova I, Zanzonico P, Ageyeva L, Beresten T, Dyomina E . Imaging hNET reporter gene expression with 124I-MIBG. J Nucl Med. 2007; 48(5):827-36. DOI: 10.2967/jnumed.106.037812. View

Taggart D, Dubois S, Matthay K . Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma. Q J Nucl Med Mol Imaging. 2008; 52(4):403-18. View

Sharp S, Shulkin B, Gelfand M, Salisbury S, Furman W . 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma. J Nucl Med. 2009; 50(8):1237-43. DOI: 10.2967/jnumed.108.060467. View

Dubois S, Matthay K . Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma. Nucl Med Biol. 2008; 35 Suppl 1:S35-48. PMC: 2633223. DOI: 10.1016/j.nucmedbio.2008.05.002. View

Stabin M, Sparks R, Crowe E . OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005; 46(6):1023-7. View

Autret D, Bitar A, Ferrer L, Lisbona A, Bardies M . Monte Carlo modeling of gamma cameras for I-131 imaging in targeted radiotherapy. Cancer Biother Radiopharm. 2005; 20(1):77-84. DOI: 10.1089/cbr.2005.20.77. View

WAXLER S, Enger M . Organ weights and obesity in mice. J Nutr. 1954; 54(2):209-14. DOI: 10.1093/jn/54.2.209. View

10.

Taggart D, Han M, Quach A, Groshen S, Ye W, Villablanca J . Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. J Clin Oncol. 2009; 27(32):5343-9. PMC: 2773221. DOI: 10.1200/JCO.2008.20.5732. View

11.

Mueller S, Matthay K . Neuroblastoma: biology and staging. Curr Oncol Rep. 2009; 11(6):431-8. DOI: 10.1007/s11912-009-0059-6. View

12.

Matthay K, Quach A, Huberty J, Franc B, Hawkins R, Jackson H . Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study. J Clin Oncol. 2009; 27(7):1020-5. PMC: 2738616. DOI: 10.1200/JCO.2007.15.7628. View

13.

Iavarone A, Lasorella A, Servidei T, Riccardi R, Troncone L, Mastrangelo R . Biology of metaiodobenzylguanidine interactions with human neuroblastoma cells. J Nucl Biol Med (1991). 1991; 35(4):186-90. View

14.

Gregory R, Hooker C, Partridge M, Flux G . Optimization and assessment of quantitative 124I imaging on a Philips Gemini dual GS PET/CT system. Eur J Nucl Med Mol Imaging. 2009; 36(7):1037-48. DOI: 10.1007/s00259-009-1099-8. View

15.

Barrett J, Joyal J, Hillier S, Maresca K, Femia F, Kronauge J . Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution. Cancer Biother Radiopharm. 2010; 25(3):299-308. DOI: 10.1089/cbr.2009.0695. View

16.

Gaze M, Chang Y, Flux G, Mairs R, Saran F, Meller S . Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma. Cancer Biother Radiopharm. 2005; 20(2):195-9. DOI: 10.1089/cbr.2005.20.195. View

17.

Wieland D, Brown L, Tobes M, Rogers W, Marsh D, Mangner T . Imaging the primate adrenal medulla with [123I] and [131I] meta-iodobenzylguanidine: concise communication. J Nucl Med. 1981; 22(4):358-64. View

18.

Dickson P, Hamner B, Ng C, Hall M, Zhou J, Hargrove P . In vivo bioluminescence imaging for early detection and monitoring of disease progression in a murine model of neuroblastoma. J Pediatr Surg. 2007; 42(7):1172-9. DOI: 10.1016/j.jpedsurg.2007.02.027. View

19.

Lee C, Wahnishe H, Sayre G, Cho H, Kim H, Hernandez-Pampaloni M . Radiation dose estimation using preclinical imaging with 124I-metaiodobenzylguanidine (MIBG) PET. Med Phys. 2010; 37(9):4861-7. PMC: 2937055. DOI: 10.1118/1.3480965. View

20.

Carlin S, Mairs R, McCluskey A, Tweddle D, Sprigg A, Estlin C . Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumors. Clin Cancer Res. 2003; 9(9):3338-44. View